Jiangzhong Pharmaceutical Co Ltd (600750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-2.91 Million ≈ $-425.37K USD) by net assets (CN¥4.70 Billion ≈ $688.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Jiangzhong Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Jiangzhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jiangzhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangzhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
-0.012x |
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
0.112x |
|
Beijing Cisri Gaona Materials Tech
SHE:300034
|
-0.004x |
|
Qingdao Sentury Tire Co Ltd
SHE:002984
|
0.014x |
|
Blackstone Digital Infrastructure Trust Inc.
NYSE:BXDC
|
N/A |
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
0.100x |
|
EIH Limited
NSE:EIHOTEL
|
0.054x |
|
Treasury Wine Estates Limited
F:T7W
|
0.012x |
Annual Cash Flow Conversion Efficiency for Jiangzhong Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Jiangzhong Pharmaceutical Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Jiangzhong Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.70 Billion ≈ $688.21 Million |
CN¥970.87 Million ≈ $142.07 Million |
0.206x | +17.40% |
| 2024-12-31 | CN¥4.47 Billion ≈ $654.34 Million |
CN¥786.25 Million ≈ $115.05 Million |
0.176x | -21.44% |
| 2023-12-31 | CN¥4.63 Billion ≈ $677.30 Million |
CN¥1.04 Billion ≈ $151.58 Million |
0.224x | -1.26% |
| 2022-12-31 | CN¥4.51 Billion ≈ $659.65 Million |
CN¥1.02 Billion ≈ $149.51 Million |
0.227x | +13.26% |
| 2021-12-31 | CN¥4.58 Billion ≈ $670.56 Million |
CN¥917.04 Million ≈ $134.19 Million |
0.200x | +13.06% |
| 2020-12-31 | CN¥4.25 Billion ≈ $622.10 Million |
CN¥752.50 Million ≈ $110.11 Million |
0.177x | +8.34% |
| 2019-12-31 | CN¥3.92 Billion ≈ $574.26 Million |
CN¥641.18 Million ≈ $93.82 Million |
0.163x | +9.32% |
| 2018-12-31 | CN¥3.25 Billion ≈ $476.08 Million |
CN¥486.25 Million ≈ $71.15 Million |
0.149x | +248.77% |
| 2017-12-31 | CN¥2.92 Billion ≈ $426.61 Million |
CN¥124.93 Million ≈ $18.28 Million |
0.043x | -83.94% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.77 Million |
CN¥698.05 Million ≈ $102.15 Million |
0.267x | +23.02% |
| 2015-12-31 | CN¥2.35 Billion ≈ $344.55 Million |
CN¥510.78 Million ≈ $74.74 Million |
0.217x | +29.69% |
| 2014-12-31 | CN¥2.13 Billion ≈ $312.15 Million |
CN¥356.80 Million ≈ $52.21 Million |
0.167x | +218.82% |
| 2013-12-31 | CN¥2.13 Billion ≈ $312.16 Million |
CN¥111.92 Million ≈ $16.38 Million |
0.052x | -52.42% |
| 2012-12-31 | CN¥2.05 Billion ≈ $300.43 Million |
CN¥226.38 Million ≈ $33.13 Million |
0.110x | +25.64% |
| 2011-12-31 | CN¥1.92 Billion ≈ $280.62 Million |
CN¥168.30 Million ≈ $24.63 Million |
0.088x | -29.76% |
| 2010-12-31 | CN¥1.78 Billion ≈ $260.34 Million |
CN¥222.29 Million ≈ $32.53 Million |
0.125x | -64.56% |
| 2009-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
CN¥378.32 Million ≈ $55.36 Million |
0.353x | +27.13% |
| 2008-12-31 | CN¥969.41 Million ≈ $141.86 Million |
CN¥268.87 Million ≈ $39.34 Million |
0.277x | +51.28% |
| 2007-12-31 | CN¥837.97 Million ≈ $122.62 Million |
CN¥153.63 Million ≈ $22.48 Million |
0.183x | +148.45% |
| 2006-12-31 | CN¥748.62 Million ≈ $109.55 Million |
CN¥55.24 Million ≈ $8.08 Million |
0.074x | -73.89% |
| 2005-12-31 | CN¥702.13 Million ≈ $102.74 Million |
CN¥198.45 Million ≈ $29.04 Million |
0.283x | +612.79% |
| 2004-12-31 | CN¥662.81 Million ≈ $96.99 Million |
CN¥26.28 Million ≈ $3.85 Million |
0.040x | -67.88% |
| 2003-12-31 | CN¥639.80 Million ≈ $93.62 Million |
CN¥78.98 Million ≈ $11.56 Million |
0.123x | -25.18% |
| 2002-12-31 | CN¥575.21 Million ≈ $84.17 Million |
CN¥94.90 Million ≈ $13.89 Million |
0.165x | +120.25% |
| 2001-12-31 | CN¥551.04 Million ≈ $80.63 Million |
CN¥41.28 Million ≈ $6.04 Million |
0.075x | -66.43% |
| 2000-12-31 | CN¥545.76 Million ≈ $79.86 Million |
CN¥121.77 Million ≈ $17.82 Million |
0.223x | +625.92% |
| 1999-12-31 | CN¥516.08 Million ≈ $75.52 Million |
CN¥-21.89 Million ≈ $-3.20 Million |
-0.042x | -3.26% |
| 1998-12-31 | CN¥277.86 Million ≈ $40.66 Million |
CN¥-11.42 Million ≈ $-1.67 Million |
-0.041x | -- |
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsu… Read more